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Abstract
Background: The surveillance of subjects at risk of pancreatic cancer is restricted to clinical research; the incidence
of familial pancreatic cancer needs to be better established. Thus, we aimed to evaluate the frequency of familial
pancreatic cancer in a population of hospitalized patients with pancreatic cancer.
Methods: A retrospective study based on the hospital charts of patients discharged with a diagnosis of pancreatic
cancer. One hundred and eighty-seven patients or their relatives were called for a phone interview.
Results: There were 97 males (51.9 %) and 90 (48.1 %) females. The overall mean ± SD age was 67.3 ± 11.8 years;
the age of males was similar to that of females (P = 0140). The mean size of the tumors found was 36.3 ± 17.4 mm
(range of 5–110 mm); it was related to gender but was not related to the site of the tumor or the age of the
patient. Regarding genetic diseases, three females (1.6 %) had familial adenomatous polyposis; three patients
(1 male and two females) (1.6 %) had at least one relative with pancreatic cancer whereas only one 80-year old
male patient (0.5 %) had two relatives affected by pancreatic cancer (the mother had died at the 65 years of age
and the brother had died at 75 years of age).
Conclusions: The frequency of familial pancreatic ductal adenocarcinoma is small, but its importance, from the
point of view of early diagnosis, is not negligible and patients with a risk of familial cancer merit an appropriate
clinical follow-up.
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Background
Pancreatic cancer is the fourth leading cause of cancer
death in Western countries [1], and its incidence and
mortality is increasing [2]. Its incidence varies widely in
different populations, suggesting the important role of
environmental risk factors, lifestyle and genetic factors
[3]. Given the low incidence of pancreatic cancer, screen-
ing in the general population is still under debate due to
the limited number of cases [4]. However, the presence of
a group of individuals having an increased risk of develop-
ing pancreatic cancer has been defined; people who have a
genetic or somatic condition associated with a 5–10 fold
increased relative risk should be involved in a surveillance
program for prevention or early detection, with the aim of
reducing mortality by means of a precocious surgical re-
section [5]. Surveillance programs for people at risk have
so far been generally limited to clinical trials, but acquiring
a deeper understanding of this complex field and the
growing need for treatment of patients with precancerous
lesions using a minimally invasive approach, becomes
increasingly necessary [6]. Pancreatic preventive sur-
gery should be performed in centers with a high level
of expertise in order to reduce the complications re-
lated to this type of intervention [7]. Data regarding
the incidence of familial cancer in the population are
not well established. The incidence in Northern Italy
has recently been estimated at 0.6 % of pancreatic
adenocarcinomas [8].
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The purpose of this study was, therefore, to assess the
frequency of familial pancreatic cancer in a population
treated in our Hospital. The ancillary endpoints were to
assess other risk factors depending on the lifestyle of the
population, such as smoking, alcohol, coffee, over-
weight/obesity, diabetes and also other types of cancer,
both synchronous and metachronous, associated with
pancreatic cancer.
Methods
This was a retrospective study based on hospital discharge
records regarding codes 157.0 and 157.1 of the Italian
Classification ICD-9-CM [9] from May 2011 to December
2013. All patients were selected from St. Orsola-Malpighi
Hospital in Bologna at first presentation for diagnostic
and therapeutic evaluation for pancreatic cancer.
As reported in Fig. 1, 340 cases were present in the
hospital database of whom 187 patients were selected
and constituted our study population; these patients or
their relatives were contacted by telephone on March
and April 2014 and 148 patients (79.1 %) were still alive
and they were able to give information. The data re-
quested by phone interview were those which were lack-
ing in the hospital charts of patients, such as smoking,
coffee and alcohol habits and clinical data (diabetes,
presence of pain, etc.) and was carried out by an experi-
enced physician (RP).
All radiologic studies were reviewed by a dedicated
radiologist (LC). Regarding the imaging techniques
computed tomography (CT) and magnetic resonance
imaging (MRI) with or without magnetic resonance
cholangiopancreatography (MRCP) according to the
protocols in use in our hospital. Endoscopic ultrasound
(EUS) was performed if clinically appropriate.
Since this was a retrospective study, the “post hoc” sam-
ple size was calculated. Based on an incidence of familial
pancreatic cancer ranging from 0.4 to 1 % of all diagnosed
pancreatic cancer (mean 0.6 %), taking into account an
alpha error of 0.05 and a cumulative incidence of familial
pancreatic cancer of 2.1 % in our population of 187 pa-
tients, the power of the dichotomous endpoint (familial
pancreatic cancer vs. non familial pancreatic cancer) for
one sample study was 64.6 %; thus, this latter figure means
that the study was not underpowered [10].
Ethics
The study was approved by the Senior Staff Committee of
the Department of Radiology of the University of Bologna
and was carried out in accordance with the Helsinki
Declaration of the World Medical Association. All study
participants gave informed consent.
Statistics
The descriptive statistics applied were means, standard
deviations (SDs) and ranges as well as absolute and rela-
tive frequencies. Non parametric statistics were applied:
the Mann Whitney U test and the Pearson chi-squared
test were applied where appropriate. All statistical evalu-
ations were carried out by running SPSS version 13.0 for
Windows. Two-tailed P values less than 0.05 were con-
sidered statistically significant.
Results
Of the 187 patients, 97 were male (51.9 %) and 90
(48.1 %) were female. The average age of the entire
study population was 67.3 ± 11.8 years (range 31-88
years). The average age of the males was 66.1 ± 11.4
and that of females was 68.5 ± 10.7 (P = 0140). The
Fig. 1 Flow chart reporting how the selection of patients enrolled in the study was made
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body mass index (BMI) in the entire population was
24.7 ± 4.1 kg/m2 (range 15.6 to 44.6 kg/m2). The BMI
was similar (P = 0.659) in males (24.5 ± 3.5) and in
females (25.0 ± 4.7). According to the World Health
Organization (WHO) classification [11], 5.3 % were
underweight, 50.0 % were normal weight, 38.2 % were
overweight and 6.6 % were obese. There was no differ-
ence (P = 0.735) in the distribution of the BMI according
to the various classes of BMI related to the sex of the
patients. Regarding alcohol habit, 45 (24.1 %), of the 187
patients studied were alcohol users (28 males and 17
females) and the difference between drinkers, according to
sex, was not statistically significant (P = 0.077). Ninety-
three patients were smokers (49.70 %), and male smokers
(61, 62.9 %) were statistically more numerous than female
smokers (32, 35.6 %; P < 0.001). One hundred and two pa-
tients (54.5 %) were coffee drinkers, 54 males (52.9 %) and
48 females (47.1 %; P = 0.771). Regarding diabetes mellitus,
one male patient (0.5 %) had diabetes mellitus type I, 61 (38
males and 23 females, 32.6 %) had diabetes mellitus type II
and three (one male and two females, 1.6 %) had diabetes
mellitus found at time of the diagnosis of pancreatic cancer.
The frequency of males with diabetes was similar to that of
females (P = 0.152). With regard to the localization of the
pancreatic tumor, the tumor was localized in the head of
the pancreas in 112 patients (59.9 %), in the body in 16 pa-
tients (8.6 %), in the tail in 21 patients (11.2 %), in the
head-body in 17 patients (9.1 %) and in the body-tail in 21
(11.2 %); there were no differences regarding sex. Intraduc-
tal papillary mucinous neoplasms (IPMNs) were found to
be associated with the pancreatic mass in 15 patients
(8.0 %, 7 males and 8 females, P = 0.788) and it was of
multifocal type in 3 patients (1.6 %). Eleven (5.9 %) of the
187 patients had a synchronous carcinoma and 24 (12.8 %),
metachronous cancer with no difference between males
and females (P = 0.540 and 0.283, respectively). Among the
eleven patients having synchronous and the 24 having
metachronous cancers, the primary cancer does not have a
hint to a hereditary diagnosis.
The size of the mass were 36.3 ± 17.4 mm (range of
5–110 mm). The dimensions were related to sex
(males: 39.4 ± 18.4, females 33.0 ± 15.6) (P = 0.039) but
were not related to the location or age of the patients.
Of the 187 patients, 130 (69.5 %) had a preoperative
diagnosis, 91 (48.7 %) were diagnosed during surgery
and 24 (12.8 %) were diagnosed both before and after
surgery. Of the 115 patients undergoing surgery, 91
had resection surgery (79.1 %) and 24 had derivative
surgery (20.9 %).
Imaging techniques
One hundred and eighty-one of the 187 patients
(96.8 %) underwent contrast-enhanced multidetector
computed tomography, 6 (3.2 %), magnetic resonance
imaging, 19 patients MRI and MRCP (10.2 %) and 60
(33.1 %) with EUS. Of the 6 patients who did not
undergo the CT, three patients had undergone MRI, two
patients MRI with MRCP and one patient EUS.
Familiality
Regarding genetic diseases, three female patients (1.6 %)
had familial adenomatous polyposis (FAP). In addition,
three patients (1 male and 2 females) (1.6 %) had at least
one relative with pancreatic cancer (two sisters, one
daughter) while only one patient 80 years of age (0.5 %)
had two family members (mother 65 years of age and
brother 75 years of age) who had been diagnosed with
pancreatic cancer. Thus, familial pancreatic cancer was
found in 2.1 % of our population (3 subjects with FAP
and one subject having with two relatives who died from
pancreatic cancer).
Discussion
This study states the reasonable hypothesis that a signifi-
cant proportion of patients presenting with pancreatic can-
cer have a familial incidence such which this retrospective
study identified.
It has been reported that in a study involving 570
families and including 9204 relatives whose probands
were 3- to 5-fold more often heavy smokers than the
general population, and 9.3 % of them reported a posi-
tive family history of pancreatic cancer; in addition, in
first-degree relatives, only mortality from pancreatic
cancer was significantly increased and the lifetime risk
of dying from pancreatic cancer was 4.1 % for the rela-
tives of all probands, and was 7.2 % for the relatives of
probands who developed disease prior to 60 years of
age [12]. These data suggest that genetic susceptibility
to pancreatic cancer may be attributable to moderate-
to low-penetrance genes. Several guidelines have also
been developed to manage these high-risk individuals
[13, 14] and registries have been established [15, 16] in
order to better investigate this topic. However, there
are no data regarding the incidence of familial pancre-
atic cancer in a real world of hospitalized patients.
Thus, our study retrospectively evaluated all patients
suffering from pancreatic cancer treated in Sant’Orsola-
Malpighi Hospital in a period of three years. Regarding
the primary endpoint of the study, only 1.6 % of patients
had at least one relative with pancreatic adenocarcin-
oma while 0.5 %, had a family history of familial adeno-
carcinoma. Pancreatic cancer has a high mortality rate
but its low incidence, together with the inability to arrive
at a diagnosis using low cost imaging methods, does not
seem to justify the execution of screening the general
population, and it is therefore important to try to inter-
vene first on the risk factors, such as smoking, coffee,
alcohol and diet [17]. Based on the observations made in
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this study with respect to cases of familial pancreatic can-
cer, the introduction of screening at least 10 years before
the age of the youngest family member affected would be
recommended with the use of imaging methods, such as
MRI and/or CT so that early intervention can be carried
out with resection surgery. It should also be noted that
our percentage of patients who should be screened is simi-
lar to that of another Italian study [8] and it would be ap-
propriate, given the low number of patients to be
followed, to abandon the current lack of interest regarding
pancreatic cancer, at least in the familial form [18]. Only
one of our patients was diagnosed at an advanced age
and had never undergone a radiological investigation
for screening as recommended by the Italian guidelines
for familial cancer [13]. In addition, 1.6 % of patients
had a tumor associated with FAP; this issue merits bet-
ter investigation in clinical practice because screening
for colorectal carcinoma may add useful information in
selecting patients with FAP, and these patients should
also be investigated and followed for the development
of pancreatic cancer [19]. It is possibly that the future
development of diagnosing the predisposition of familial
pancreatic cancer is to evaluate genomic modifications;
in fact, it has been recently reported that prevalence of
mutations among familial pancreatic cancer probands
was 1.2 % for BRCA1, 3.7 % for BRCA2, 0.6 % for
PALB2, and 2.5 % for CDKN2A [20]. In addition, the
same authors reported that familial pancreatic cancer
probands carry mutations in the four genes with a sig-
nificant more high frequency (8.0 %) than nonfamilial
pancreatic cancer probands (3.5 %) [20]. On the other
hand, other authors have been also reported that eleven
pathogenic mutations have identified (3 in ATM, 1 in
BRCA1, 2 in BRCA2, 1 in MLH1, 2 in MSH2, 1 in MSH6,
and 1 in TP53) and that the prevalence of mutations was
3.8 %; the carrier status was associated significantly with
breast cancer in the proband or first-degree relative, and
with colorectal cancer in the proband or first-degree rela-
tive, but not family history of pancreatic cancer, age at
diagnosis, or stage at diagnosis [21]. Thus, we need of fur-
ther studies on this topic but genetic testing of multiple
relevant genes in probands with a positive family history
of cancer is reasonable.
Other data from our study confirmed what is already
known, i.e. that approximately half of the study population
smoked [20], about 50 % habitually consumed coffee [20]
and less than a quarter of the patients (24.1 %) drank
alcohol [22]. It has been suggested that obesity is a risk
factor for pancreatic cancer [23], but our data seemed to
confirm that, in the majority of cases (50.0 %), Italian pa-
tients were of normal weight, 38.2 % were overweight and
only 6.6 % were obese. Probably, the diet of the Italian
population is different from the American diet so the risk
related to obesity does not appear to be evident [24]. Our
data were in line with those of the literature regarding the
location of pancreatic cancer; in fact, this tumor is most
frequently localized in the head of the pancreas (60 %)
[25], and the size of the mass, greater than 3 cm, means
that the diagnosis is unfortunately still too late [26]. An in-
teresting datum was that IPMNs were found to be associ-
ated with a pancreatic mass in 8 % of the patients and was
multifocal in 3 patients. This indicated that pancreatic
adenocarcinoma probably arises from the degeneration of
an unrecognized mucinous tumor [27]; hence, the import-
ance of a proper diagnosis and follow-up of mucinous
cystic lesions [28]. Another interesting fact is that of the
187 patients studied, approximately 6.0 % had a synchron-
ous carcinoma and 13 % metachronous cancer; these pa-
tients require a different clinical approach which has not
yet been defined. Even if our study suffers from the limita-
tions of retrospective studies, this is the first study, how-
ever, which evaluated the incidence of familial pancreatic
cancer in an unselected hospitalized population; the post-
hoc analysis revealed that the population study was not
unpowered. In addition, it should be pointed out that only
62 % of the patients studied (187/301) had a correct Clas-
sification ICD-9-CM; much effort should be made to im-
prove the correct application of Classification ICD-9-CM
as also suggested by the Italian Association of Medical
Oncologists [29]. One problem of studies regarding familial
pancreatic cancer is the method used to assess the family
history of these subjects. PancPro is a Bayesian modeling
framework used to assess the pancreatic cancer risk of
patients with a family history of pancreatic cancer [30].
However, in this study, information was collected using a
questionnaire and no natural language processing system
techniques. Using PancPro, it has been reported that the
sensitivity of finding a subject with a family history of
pancreatic cancer is 93 %, the positive predictive value is
97 % when family history is extracted, but this method
considers only family histories [31] and does not extract
specific family members or classify family members as pri-
mary, secondary and unknown relatives [32]. An algorithm
has recently been proposed based on the Unstructured In-
formation Management Architecture (UIMA) framework
consisting of section segmentation, relation discovery and
negation detection [32]. This system was evaluated using
data from two institutions, and the results showed that
rule-based natural language processing approaches for
specific information extraction tasks are portable across
institutions; however, customization of the algorithm re-
garding the new dataset improves its performance and this
may increase the possibility of detecting the familial origin
of pancreatic cancer.
Conclusions
In conclusion, the frequency of familial pancreatic ductal
adenocarcinoma in a non-selected series of patients,
Mughetti et al. BMC Gastroenterology  (2016) 16:6 Page 4 of 5
even if retrospective, is low, but its importance from the
point of view of early diagnosis is not negligible and pa-
tients with familial cancer risk require adequate follow-
up [17]. To really increase the possibility of finding sub-
jects having familial pancreatic cancer, a new approach
based on the Unstructured Information Management
Architecture (UIMA) framework [32] should be tested
in a large multicenter study. Finally, it has been demon-
strated that screening for familial pancreatic cancer is
cost-effective [33] and close cooperation between practi-
tioners and referral pancreatological units may be of
benefit both for the patient and for better economic re-
source allocation regarding health welfare.
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